Condition (MeSH)
Chondrosarcoma, Clear Cell
ClinicalTrials.gov lists 2 trials for Chondrosarcoma, Clear Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Chondrosarcoma, Clear Cell itself; the rest are tagged with a narrower condition beneath it.
When did Chondrosarcoma, Clear Cell trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Chondrosarcoma, Clear Cell trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 1 |
How many Chondrosarcoma, Clear Cell trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Chondrosarcoma, Clear Cell trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 1 |
Which serious adverse events do Chondrosarcoma, Clear Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify | 5 | 1 |
| Adult respiratory distress syndrome | 3 | 1 |
| Sepsis | 3 | 1 |
| ANEMIA | 2 | 1 |
| General disorders and administration site conditions - Other, specify | 2 | 1 |
Showing 5 of 10 adverse events.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: publications, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.